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Abstract 
Background: Attention deficit hyperactivity disorder (ADHD) has a strong genetic component. The study is aimed to 
test the association of 34 polymorphisms with ADHD symptomatology considering the role of clinical subtypes and 
sex in a Spanish population.
Methods: A cohort of ADHD 290 patients and 340 controls aged 6–18 years were included in a case–control study, 
stratified by sex and ADHD subtype. Multivariate logistic regression was used to detect the combined effects of multi‑
ple variants.
Results: After correcting for multiple testing, we found several significant associations between the polymorphisms 
and ADHD (p value corrected ≤0.05): (1) SLC6A4 and LPHN3 were associated in the total population; (2) SLC6A2, 
SLC6A3, SLC6A4 and LPHN3 were associated in the combined subtype; and (3) LPHN3 was associated in the male 
sample. Multivariable logistic regression was used to estimate the influence of these variables for the total sample, 
combined and inattentive subtype, female and male sample, revealing that these factors contributed to 8.5, 14.6, 2.6, 
16.5 and 8.5 % of the variance respectively.
Conclusions: We report evidence of the genetic contribution of common variants to the ADHD phenotype in four 
genes, with the LPHN3 gene playing a particularly important role. Future studies should investigate the contribution 
of genetic variants to the risk of ADHD considering their role in specific sex or subtype, as doing so may produce more 
predictable and robust models.
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Background
Attention deficit hyperactivity disorder (ADHD) is one 
of the most common neurodevelopmental disorders in 
young people, affecting 5.3 % of school-age children [1]. 
Also, approximately 65  % of children with ADHD con-
tinue to show symptoms in adulthood [2].
ADHD is a complex and heterogeneous disorder and 
its etiology remains unidentified to date [3]. Family, twin 
and adoption studies have shown that different genes play 
an important role in the etiology of ADHD, and the mean 
estimated heritability in childhood is 76 % [4], suggesting 
that ADHD is one of the psychiatric disorders with the 
most substantial genetic component.
Many association studies have investigated genetic 
susceptibility to ADHD. However, efforts to replicate 
these results have often been poor, yielding inconsistent 
results as demonstrated in meta-analysis of candidate 
gene studies [5], but also from linkage studies [6] and 
genome-wide association studies (GWAS) [7]. ADHD is a 
complex genetic disorder, in which environmental factors 
are involved and play a key role [7].
The aim of this study was to test whether previously 
reported common genetic variants (34 polymorphisms 
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in 18 genes) influence ADHD susceptibility in Spanish 
patients.
Based on the etiology of ADHD, we chose candidate 
genes that encode functionally relevant proteins involved 
in noradrenergic (SLC6A2, ADRA2A), dopaminergic 
(SLC6A3, DRD2, DRD4, COMT, DDC), and serotoner-
gic (SLC6A4, HTR2A, HTR2C) neurotransmission. In 
addition, we evaluated other candidate genes frequently 
reported as being related with ADHD such as STS, 
FADS2 and SNAP25. Finally, significantly reported genes 
from GWAS studies such as CDH13, GFOD1, SLC6A9 
and GRM7, and genes revealed in linkage as playing a role 
in ADHD susceptibility such as LPHN3 were included in 
the study (Table 1).
Methods
Patients and controls
A total of 320 Spanish ADHD patients of Caucasian 
ancestry and 344 healthy children and adolescents of 
the same nationality and ancestry were initially included 
in this case–control study. After a quality control pro-
cedure, 290 patients and 340 controls were included in 
the final analysis. ADHD patients were recruited and 
evaluated at Fundación Jiménez Díaz University Hos-
pital, whereas the control sample was recruited at both 
the aforementioned hospital and primary and second-
ary schools. Exclusion criteria for the control sample 
included ADHD diagnosis or suspicion of symptomatol-
ogy, and chronic illness. The sample (cases and controls) 
comprised subjects between the ages of 6 and 18 years. 
Even though we did not test for the structure in our 
cohort, a genome wide study of 800 subjects distrib-
uted throughout Spain discarded the presence of genetic 
stratification [8].
The study protocol was approved by the Research 
Ethics Committee of the IIS-Fundación Jiménez Díaz 
University Hospital. The study was conducted accord-
ing to the tenets of 2008 declaration of Helsinki. Before 
enrollment, parents or legal guardians signed a written 
informed consent form after the study objectives and 
procedures had been explained.
Clinical assessment
Subjects were included in the study only after a diagno-
sis of ADHD was made by specialist clinicians according 
to the diagnostic and statistical manual of mental disor-
ders, fourth edition, text revision (DSM-IV TR) [9]. Each 
diagnosis was checked by two clinical researchers. Where 
consensus could not be reached, cases were reviewed by 
an additional clinical researcher. The children were clas-
sified into the following ADHD subtypes: predominantly 
inattentive subtype, predominantly hyperactive/impul-
sive subtype and combined subtype.
All cases included underwent clinical assessment 
using the strengths and difficulties questionnaire (SDQ) 
for detecting psychological morbidity [10]. Severity 
of ADHD symptoms was based on the ADHD rating 
scale-IV (ADHD RS-IV) [11], whereas overall psychoso-
cial functioning was assessed by means of the children’s 
global assessment scale (CGAS) and the clinical global 
impression scale (CGI) [12]. Information on obstetric 
complications, developmental features, medical and psy-
chiatric history, family history, and treatment histories 
were obtained through maternal interview.
Exclusion criteria included other psychotic disorders 
(bipolar disorder or schizophrenia among others), perva-
sive developmental disorders, intelligence quotient (IQ) 
<70, and neurological damage.
DNA extraction and genotyping
Genomic DNA samples were obtained either from 
peripheral blood lymphocytes using an automatic DNA 
extractor (BioRobot EZ1, Qiagen, Hilden, Germany) or 
from saliva using the Oragene DNA self-collection kit 
(DNA Genotek, Kanata, Ontario, Canada), according to 
the manufacturer’s recommendations. DNA concentra-
tion and sample quality were assessed spectrophoto-
metrically (NanoDrop® ND-1000 Spectrophotometer, 
Wilmington DE, USA).
Candidate polymorphisms were selected based on 
their relevance as indicated in the literature on ADHD 
(Table 1).
All single nucleotide polymorphisms (SNPs) were 
typed using TaqMan Assays-on-Demand or pre-designed 
SNP genotyping assays following the manufacturer’s 
instructions (Applied Biosystems, Foster City, CA, USA). 
PCR and allelic discrimination assays were run using the 
LightCycler 480 System (Roche Diagnostics, Mannheim, 
Germany). The results were evaluated using LightCycler® 
480 software, version 1.5 (Roche Diagnostics, Mannheim, 
Germany).
For each variable number tandem repeats (VNTR) pol-
ymorphism, subjects were categorized into three geno-
types according to the risk allele previously described 
[5] as follows: SLC6A3 3´UTR VNTR (10/10, 10/-, -/-), 
SLC6A3 intron8 VNTR (6/6, 6/-, -/-), DRD4 promoter 
duplication VNTR (L/L, L/S, S/S), DRD4 exon3 VNTR 
(7/7, 7/-, -/-), SLC6A4 promoter VNTR (L/L, L/S, S/S), 
SLC6A4 intron2 VNTR (10/10, 10/-, -/-). Detection of 
VNTR polymorphisms was performed using fragment 
analysis. PCR products were visualized on an ABI Prism 
3130xl DNA sequencer (Applied Biosystems Foster City, 
CA). The results were evaluated using the GeneMapper 
software, version 4.0 (Applied Biosystems, Foster City, 
CA). Primer sequences and conditions are available upon 
request.
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Statistical analysis
For the case–control association study, Hardy–Weinberg 
equilibrium for all genetic variants was assessed only in 
the control population because deviance from HWE in 
cases sample might be an indication of association with 
the disorder; variants not in HWE (p value < 0.01) were 
excluded from the analysis.
A quality-control procedure was applied to the geno-
type data. The threshold applied in genotype call rates 
per sample and per polymorphism was 80 %.
Logistic regression was used to examine the association 
of the genotype frequencies with the disorder. The effect 
of the genetic variant on outcome was adjusted by sex 
and age (covariates). To reduce genetic heterogeneity and 
to test if there were different genetic factors for the dis-
tinct ADHD subtypes, ADHD patients were subdivided 
into two main diagnostic groups, combined ADHD and 
inattentive ADHD. The hyperactive-impulsive ADHD 
subtype was not considered due to its small sample size. 
To examine differences between males and females, sex-
stratified analyses were performed.
Logistic regression analysis was performed to analyze 
the five inheritance models (codominant, dominant, 
recessive, overdominant and log-additive) [13] using 
Table 1 Description of the 34 polymorphisms analysed within 18 genes for ADHD
Position in the gene: a upstream gene variant, b promoter variant, c exon variant, d intron variant, e 3′UTR variant, f downstream gene variant
Gene Description Variant Reference
SLC6A2 Norepinephrine transporter rs28386840a [19]
r5569c [5]
ADRA2A Adrenergic receptor alpha 2A rs1800544a [5]
rs553668e [5]
SLC6A3 Dopamine transporter rs2550948b [22]
rs2652511b [22]
rs11564750a [22]
3′UTR VNTRe [5]
Intron8 VNTRd [5]
DRD2 Dopamine receptor D2 rs1800497f [21]
DRD4 Dopamine receptor D4 rs3758653a [20]
Exon3 VNTRc [21]
Promoter duplicationb [21]
COMT Catechol‑O‑methyltransferase rs4680c [5]
rs4818c [50]
DDC Dopa decarboxylase rs6592961d [51]
SLC6A4 Serotonin transporter Promoter VNTRb [5]
Intron2 VNTRd [5]
HTR2A Serotonin‑2A receptor rs7322347d [51]
HTR2C Serotonin‑2C receptor rs6318c [52]
SLC9A9 Glycine transporter rs9810857f [53]
GRM7 Glutamate receptor, metabotropic 7 rs3792452d [54]
SNAP25 Synaptosomal‑associated protein 25kDA rs3746544e [5]
CDH13 Cadherin 13 rs6565113d [20]
GFOD1 Glucose‑fructose oxidoreductase domain containing 1 rs552655d [20]
STS Steroid sulfatase rs12861247d [55]
rs17268988d [55]
FADS2 Fatty acid desaturase 2 rs498793d [31]
LPHN3 Latrophilin 3 rs1397548c [17]
rs2305339d [17]
rs6551655d [17]
rs1868790d [24]
rs6813183d [24]
rs6858066d [24]
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SNPstats software [14] and expressed as odds ratio (OR), 
95 % confidence interval (CI) and nominal significant dif-
ferences (p value ≤  0.05). If various inheritance models 
had significant results, we chose the one with the lowest 
Akaike information criteria (AIC value).
Genotypes frequencies of variants located on chromo-
some X (HTR2C and STS genes) were analyzed only in 
females.
The Benjamini and Hochberg false discovery rate 
method was performed for multiple testing corrections 
[15]. A p value threshold of 0.05 after correction was used 
to determine significance. Risk-prediction models to 
investigate the combined impact of multiple genetic vari-
ants were applied. For this purpose, polymorphisms with 
p values ≤ 0.25 were incorporated in a forward stepwise 
multivariate logistic regression analysis and expressed as 
the OR, 95 % CI and p value.
The variability explained for each variable as meas-
ure of the effect size of the polymorphisms (defined by 
pseudo-r2) and the measure of model predictability 
(defined by AUC value) were calculated.
A post hoc analysis of statistical power was performed 
with the CaTS Power Calculator software [16] assum-
ing an OR of 1.5, disorder prevalence of 5 %, significance 
level of 0.05, and mean minor allele frequency (MAF) 
observed of 0.30. The statistical power calculated for the 
final sample included in this study (290 cases and 340 
controls) was 89, 64, and 23  % considering an additive, 
dominant and recessive model, respectively.
Results
A total of 320 patients and 344 controls were ini-
tially investigated. Thirty-four subjects were excluded 
because they showed genotype call rates <80 %. There-
fore, 290 patients and 340 controls were included in 
the final analysis. Per-marker genotype call rates were 
higher than 96 % for all variants. The genotype distribu-
tions of all polymorphisms were consistent with HWE 
(p value  >  0.01) in the control sample. The average 
age was 10.43  years (SD 2.95) for ADHD patients and 
11.05  years (SD 3.00) for the controls. 80 and 66  % of 
patients and controls were male, respectively. Clinical 
classification of the patients was the following: inatten-
tive subtype (n  =  102), hyperactive/impulsive subtype 
(n = 13) and combined subtype (n = 175). Demographic 
and clinical characteristics of the sample are reported in 
Table 2.
Logistic regression results for single markers
When the whole sample was considered (unstratified 
sample), logistic regression analysis for single markers, 
adjusted by sex and age, showed statistically significant 
results after correcting for multiple comparisons in two 
polymorphisms: SLC6A4 promoter VNTR and LPHN3 
rs2305339 (Table 3; Additional file 1: Table S1).
In the combined ADHD subtype, association was sta-
tistically significant for SLC6A2 rs28386840, SLC6A3 
rs11565750, SLC6A4 promoter VNTR and LPHN3 
rs2305339. None of the individual comparisons was sta-
tistically significant after correcting for multiple compar-
isons in the inattentive subtype (Table 3 and Additional 
file 1: Table S1).
In the logistic regression analysis for single mark-
ers, adjusted by age, none of the individual comparisons 
was statistically significant after correcting for multiple 
comparisons in the female sample. In the male sample, 
only LPHN3 rs2305339 remained statistically significant 
(Table 3 and Additional file 1: Table S1).
Multivariate logistic regression results
Figures 1 and 2 show multivariate logistic regression anal-
yses for the total ADHD sample, subtype and sex stratifi-
cation. The variables included in the model were ordered 
according to the amount of variance explained (r2).
Table 2 Demographic and clinical characteristics of ADHD 
patients and controls
ADHD patients Controls
Age
 Mean (SD) 10.43 (2.9) 11.05 (3)
 Range 6–18 6–18
Gender
 Male (%) 230 (79.3) 224 (66)
 Female (%) 60 (20.7) 116 (34)
ADHD diagnosis
 Combined type (%) 175 (60.3)
 Inattentive type (%) 102 (35.2)
 Hyperactive type (%) 13 (4.5)
Previous treatment
 Psychotherapeutic (%) 53 (18.27)
 Pharmacological (%) 22 (7.6)
 Both (%) 52 (17.9)
 No previous treatment (%) 147 (50.6)
ADHD–RS
 Mean (SD) 27 (12)
CGI score
 Mean (SD) 3.4 (0.5)
CGAS score
 Mean (SD) 69 (10)
Comorbility with (%)
 Learning disabilities 63 (21.7)
 Oppositional defiant disorder 22 (7.6)
 Conduct disorder 16 (5.5)
 Tic disorder 7 (2.4)
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In the total sample, eight polymorphisms located 
in seven genes were included in the regression equa-
tion: SLC6A4 promoter VNTR, LPHN3 (rs2305339, 
rs6551665), DRD4 exon3 VNTR, SNAP25 rs3746544, 
SLC6A3 rs11564750, SLC6A2 rs28386840 and FADS2 
rs498793. The amount of the variance explained for the 
model was 8.5 % and the AUC was 0.69 (Table 4).
In the case of the combined subtype, seven polymor-
phisms located in seven genes were included in the 
model: SLC6A4 promoter VNTR, SLC6A2 rs28386840, 
SLC6A3 rs11564750, LPHN3 rs2305339, DDC rs6592961, 
GRM7 rs3792453 and FADS2 rs498793. The amount 
of the variance explained was 14.6  % and the AUC was 
0.75. In the case of inattentive subtype, two polymor-
phisms were included in the model, LPHN3 r6551665 
and SNAP25 rs3746544. The amount of the variance 
explained for the model was 2.6 % and the AUC was 0.60 
(Table 4).
Five polymorphisms located in five genes (SLC6A3 
rs11564750, SNAP25 rs3746544, LPHN3 rs6551665, 
DRD4 exon3 VNTR and SLC6A2 rs28386840) and seven 
polymorphisms located in five genes (LPHN3 (rs2305339, 
rs6551665), SLC6A2 (rs28386840, rs5569), GRM7 
rs3792452, SLC6A4 promoter VNTR and DRD4 exon3 
VNTR) were included in the model for females and 
males, respectively. The amount of the variance explained 
for the sample including females was 16.5 % and the AUC 
was 0.77. In the case of males, the amount of the variance 
explained was 8.5 % and the AUC was 0.69 (Table 4).
Discussion
This study aimed to both determine whether differential 
genetic variants may participate in distinct ADHD sub-
types and also examine the sex-specific effects of this 
impact. Multivariate regression analyses of the effects of 
single genes were evaluated, but as ADHD is a complex 
polygenic disorder, the combined effect of multiple genes 
on the phenotype was also considered.
As seen in the logistic regression analysis for single 
markers, this study provides evidence of a strong associa-
tion between the SLC6A4 gene and ADHD in the entire 
population; and between SLC6A2, SLC6A3 and SLC6A4 
and ADHD in the combined subtype. Special attention 
should be given to the LPHN3 gene, since it was associ-
ated with the presence of ADHD in the entire population, 
the combined subtype and the male sample.
In order to clarify the genetic basis of ADHD, the effects 
of multiple risk factors were examined. In the entire sam-
ple, seven genes were included in the regression equation 
(SLC6A4, LPHN3, DRD4, SNAP25, SLC6A3, SLC6A2 and 
FADS2). The involvement of these genes in ADHD has 
been extensively studied [5, 17–23], some in Spanish pop-
ulations [24, 25]. The contribution of each gene was mod-
est, as expected for a complex genetic disorder (ranging 
Table 3 Significant results after multiple comparison correction of logistic regression analysis for single markers
OR odds ratio, CI confidence interval
p values corrected based on Benjamini and Hochberg method
Gene Variant Model Genotype Controls N (%) Cases N (%) OR (95 % CI) p value p value 
corrected
All population
L/L–L/S 241 (71.1) 239 (83.3) 1
 SLC6A4 Promoter VNTR Recessive S/S 98 (28.9) 48 (16.7) 0.52 (0.35–0.77) 0.0009 0.0153
A/A–G/G 177 (52.1) 185 (63.8) 1
 LPHN3 rs2305339 Overdominant A/G 163 (47.9) 105 (36.2) 0.57 (0.41–0.79) 0.0007 0.0153
Combined subtype
A/A 174 (51.2) 65 (37.1) 1
 SLC6A2 rs28386840 Dominant A/T–T/T 166 (48.8) 110 (62.9) 1.76 (1.19–2.59) 0.0041 0.0318
G/G 284 (83.4) 161 (92.5) 1
G/C 51 (15.1) 13 (7.5) 0.40 (0.21–0.77) 0.0026 0.0269
 SLC6A3 rs11564750 Log‑additive C/C 5 (1.5) 0 (0)
L/L–L/S 241 (71.1) 151 (87.3) 1
 SLC6A4 Promoter VNTR Recessive S/S 98 (28.9) 22 (12.7) 0.37 (0.22–0.62) 0.0001 0.0031
A/A–G/G 177 (52.1) 114 (65.1) 1
 LPHN3 rs2305339 Overdominant A/G 163 (47.9) 61 (34.9) 0.51 (0.34–0.76) 0.0008 0.0124
Male
A/A 83 (36.9) 128 (55.2) 1
 LPHN3 rs2305339 Codominant A/G 128 (56.9) 81 (34.9) 0.41 (0.28 –0.60) 0.0000 0.0001
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from 0.4 to 1.6 %). The model explained around 9 % of the 
variance; 7 % of this variance was due to genetic factors. A 
previous study, including 22 variants, found that 16 % of 
the variance was due to genetic factors [26].
In the regression equation, two genes were included in 
the inattentive subtype (LPHN3 and SNAP25) and seven 
genes (SLC6A4, SLC6A2, SLC6A3, LPHN3, DDC, GRM7 
and FADS2) in the combined subtype. A remarkable 
importance of the SLC6A4 gene was observed, account-
ing for 2.9  % of the variance, above the usual threshold 
of 2 % [27]. This study showed that the clinical subtypes 
analyzed share genetic risk factors (LPHN3), yet SNAP25 
was associated with the inattentive subtype, whereas 
SLC6A4, SLC6A2, SLC6A3, DDC, GRM7 and FADS2 
were implicated in the combined subtype. The presence 
of common as well as specific genetic variants for each 
Fig. 1 ROC curves analyses of the regression model, stratified by a 
ADHD subtype and b sex, and compared to total the population. 
AUC, area under de curve
Fig. 2 Results for variables that were included in the multivariate 
regression equation in: a the total population, and stratified analyses 
by b combined subtype, c inattentive subtype, d females and e 
males. The p values, OR 95 % CI, and pseudo r2 for the individual vari‑
ables are shown
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subtype is supported by previous studies [28, 29]. How-
ever, some of these reported associated variants differ 
between studies [24, 30–36].
The model showed a higher genetic loading for the 
variables analyzed in combined subtype (14.6 %) than in 
the inattentive subtype (2.6  %), finding consistent with 
the previously reported higher genetic loading in ADHD 
comorbid symptoms [37, 38]. It is important to note the 
importance of sex and age in the combined subtype (r2 
5.9 %) but not in the inattentive sample.
The model for the combined subtype seems to be more 
predictive than the inattentive subtype (AUC 0.75 and 
AUC 0.60, respectively) and better than the model used 
for the whole sample (AUC 0.69). This supports the idea 
that analyzing more homogeneous phenotypes facilitates 
the identification of genetic factors.
ADHD is known to have sex-based differences in sever-
ity and clinical course [39]. Herein, differences in genetic 
susceptibility between males and females were observed. 
In females, SLC6A3, SNAP25, LPHN3, DRD4 and SLC6A2 
genes showed high r2 values (range from 2 to 3.8  %). In 
males, LPHN3, SLC6A2, GRM7, SLC6A4, DRD4 and 
LPHN3 were included in the regression equation. The 
LPHN3 gene accounted for 3.4  % of ADHD variability. 
This analysis showed that genes such as DRD4, SLC6A2 
and LPHN3 were associated in both sexes, with a stronger 
effect of SLC6A3 and SNAP25 in females (r2 3.8 and 3.3 % 
respectively) and a lesser effect of GRM7 and SLC6A4 in 
males (r2 0.8  %). The association between SLC6A4 and 
male sample is supported by previous studies [40], but not 
between SLC6A3 and female sample [41].
To the best of our knowledge, sex-based differences 
in the genetic risk for ADHD have not been previously 
reported in the SNAP25 and GRM7 genes. These results 
suggest the need to explore biological evidence of sexu-
ally dimorphic effects in such genes.
The percentage of variance explained in females was 
higher (16.5  %) than in males (8.5  %). The regression 
model for girls (AUC 0.77) seems to be more predic-
tive than for boys (AUC 0.69). These results suggest that 
the set of variants analyzed has a higher genetic contri-
bution for ADHD in girls than in boys. Females are less 
frequently affected because a more extreme genetic load 
is required for the liability threshold to be surpassed 
[37, 42]. Additionally, it has been reported that females 
referred to a clinic are more prone to exhibit other dis-
ruptive behaviors [43], although this seems to be a conse-
quence of referral bias [44].
Our results add to extensive literature information 
about polymorphic variants in genes whose implication 
in ADHD is widely known through the pathophysiology 
as SLC6A2, SLC6A3, SLC6A4 and LPHN3. In some cases 
the polymorphism associated has a known functional 
implication, like rs28386840, a functional promoter vari-
ant of SLC6A2 gene. But there are also other polymor-
phisms associated with any biological meaning that could 
be in linkage disequilibrium with other unknown func-
tional variants directly involved in genetic susceptibility 
to ADHD. These findings need to be further explored 
to improve the understanding of their implication with 
ADHD.
The conflicting genetic results show the difficulty of 
replicating across genetic association studies. Often there 
is important variation in the sample reported, particu-
larly regarding the age, sex ratios and ethnic. Also, an 
accurate phenotype definition is crucial to obtain suc-
cessful results in these studies. In our study a rigorously 
diagnostic criteria was applied.
In addition, the specific effect of a gene could be dif-
ferent depending on the sets of genetic variants analyzed 
or the model of inheritance evaluated. In contrast with 
other studies, we evaluated genetic information under 
different models of inheritance without an a priori con-
sideration of possible genetic effects. This makes it eas-
ier to detect genetic effects, since different genotypes 
of the same gene could be associated with different 
phenotypes.
The most important limitation of the study was the 
modest sample size. The statistical power decreased 
when the sample was subdivided according to ADHD 
subtype or sex stratification; thus, it is difficult to deter-
mine whether negative findings were due to low sta-
tistical power or to the absence of a true biological 
association. On the contrary, we only consider associa-
tion that remain significant after multiple testing cor-
rection in the regression logistic of single markers so we 
avoid false positive (type I error) rates, giving us confi-
dent in the veracity of the results.
Conclusions
We report evidence of the genetic contribution of com-
mon variants to the ADHD phenotype in four genes, with 
the LPHN3 gene playing a particularly strong role.
Table 4 Overview of multivariate logistic regression anal-
ysis
AUC area under de curve, CI confidence interval
Trait Pseudo  
r2 (%)
AUC (CI 95 %) Genetic  
variants
All sample 8.5 0.69 (0.65–0.73) 8
Combined subtype 14.6 0.75 (0.71–0.79) 7
Inattentive subtype 2.6 0.60 (0.54–0.67) 2
Female 16.5 0.77 (0.66–0.84) 5
Male 8.5 0.69 (0.64–0.74) 7
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The most predictable model described in this study 
was for females (r2 16.5 %, AUC 0.77). As seen in this 
study, analysis of the contribution of multiple genes 
provides particularly useful insight for the effort to 
discover the genetic basis of polygenic disorders and 
multigene analysis had substantial advantages over the 
single-gene approach. However, the percentage of the 
variance in ADHD diagnosis explained remains low; 
hence, most of the genetic component in phenotypic 
variance remains unexplained when considering com-
mon variants. Additional studies including copy num-
ber variation [45, 46], exome sequencing studies [47] 
as well as gene–gene and gene-environment interac-
tions [48, 49] could clarify the genetic contribution to 
ADHD.
Future studies should investigate the contribution of 
genetic variants to the risk of ADHD considering their 
role in specific sex or subtype in order to produce more 
predictable and robust models, enabling the develop-
ment of an accurate diagnosis and hopefully improved 
treatment.
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